These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8595995)

  • 1. Maintenance strategies in Crohn's disease.
    Sachar DB
    Hosp Pract (1995); 1996 Jan; 31(1):99-106. PubMed ID: 8595995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of inflammatory bowel disease: new therapies, new drugs.
    Sutherland LR
    CMAJ; 1987 Nov; 137(9):799-802. PubMed ID: 2894889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE; Helmstädter V
    Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cryptogenetic ulcerative colitis. Our clinical experience with new therapeutic approaches].
    Cigala O; Pancallo MT; Marasco A; Della Valle M
    Clin Ter; 1990 Jul; 134(2):101-10. PubMed ID: 1979263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ulcerative colitis and Crohn disease. Early diagnosis and therapy].
    Wienbeck M; Purrmann J; Miller B
    Internist (Berl); 1986 Mar; 27(3):166-71. PubMed ID: 2872183
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature].
    Neĭman KP; Rumiantsev VG
    Eksp Klin Gastroenterol; 2006; (3):56-60. PubMed ID: 17203844
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inflammatory bowel diseases].
    Kruis W
    Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S73-5. PubMed ID: 15368174
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical aspects of ulcerative colitis in mainland China.
    Zheng JJ
    Chin J Dig Dis; 2006; 7(2):71-5. PubMed ID: 16643333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical treatment of inflammatory bowel disease.
    Singhal A; Kar P
    J Assoc Physicians India; 1995 Sep; 43(9):627-31. PubMed ID: 8773067
    [No Abstract]   [Full Text] [Related]  

  • 20. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.